Probably a bit off with your analysis. Keytruda is an immunotherapy drug (heading for US$10b this year) and the exercise is to investigate combination effect, which would massively enhance TT and Keytruda. TT would have a much much wider application, Keytruda would get a boost in efficacy. No one would be at loss if it goes well.
- Forums
- ASX - By Stock
- Qbiotics
Probably a bit off with your analysis. Keytruda is an...
-
- There are more pages in this discussion • 1,196 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)